RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+34.16%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$913M
AUM Growth
+$913M
(+14%)
Cap. Flow
-$73.3M
Cap. Flow
% of AUM
-8.04%
Top 10 Holdings %
Top 10 Hldgs %
28.56%
Holding
108
New
15
Increased
30
Reduced
36
Closed
14
Top Buys
| 1 |
Guardant Health
GH
|
$9.4M |
| 2 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$9.14M |
| 3 |
Intuitive Surgical
ISRG
|
$7.09M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$6.81M |
| 5 |
Cooper Companies
COO
|
$6.43M |
Top Sells
| 1 |
CVS Health
CVS
|
$12.1M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$12M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$11.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
$11.1M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$9.05M |
Sector Composition
| 1 | Healthcare | 93.54% |
| 2 | Financials | 0.09% |
| 3 | Energy | 0.09% |
| 4 | Technology | 0.09% |
| 5 | Communication Services | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Esperion Therapeutics
ESPR
$448M
| $39.4M | 4.31% | 660,000 +4,146 | +0.6% | +$247K |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $35M | 3.84% | 160,000 -26,000 | -14% | -$5.69M |
|
3
NovoCure
NVCR
$1.38B
| $29.5M | 3.23% | 350,000 +10,000 | +3% | +$843K |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $28.1M | 3.07% | 775,000 -250,000 | -24% | -$9.05M |
|
5
Humana
HUM
$36.5B
| $24.6M | 2.69% | 67,000 +7,000 | +12% | +$2.57M |
|
6
Nektar Therapeutics
NKTR
$568M
| $23.7M | 2.6% | 1,100,000 -100,000 | -8% | -$2.16M |
|
7
Bristol-Myers Squibb
BMY
$96B
| $21.8M | 2.39% | 340,000 -75,000 | -18% | -$4.81M |
|
8
Boston Scientific
BSX
$156B
| $20.4M | 2.24% | 451,668 +81,668 | +22% | +$3.69M |
|
9
Cigna
CI
$80.3B
| $19.4M | 2.13% | 95,000 +15,000 | +19% | +$3.07M |
|
10
Elevance Health
ELV
$71.8B
| $18.7M | 2.05% | 62,000 +2,000 | +3% | +$604K |
|
11
AbbVie
ABBV
$372B
| $18.6M | 2.04% | 210,000 +40,000 | +24% | +$3.54M |
|
12
Abbott
ABT
$231B
| $18M | 1.97% | 207,469 -12,645 | -6% | -$1.1M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $17.8M | 1.95% | 210,000 -80,491 | -28% | -$6.81M |
|
|
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $17.2M | 1.88% | 500,000 -350,000 | -41% | -$12M |
|
15
UnitedHealth
UNH
$281B
| $17.1M | 1.87% | 58,000 -19,000 | -25% | -$5.59M |
|
|
AERI
16
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $16.9M | 1.85% | 700,000 +225,000 | +47% | +$5.44M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $16.1M | 1.77% | 125,000 +25,000 | +25% | +$3.22M |
|
|
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $15.3M | 1.68% | 210,000 +10,000 | +5% | +$729K |
|
|
ALXN
19
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $15.3M | 1.67% | 141,319 -105,984 | -43% | -$11.5M |
|
20
LivaNova
LIVN
$3.08B
| $15.1M | 1.65% | 200,000 +80,000 | +67% | +$6.03M |
|
21
Jazz Pharmaceuticals
JAZZ
$7.75B
| $15M | 1.65% | 100,805 -49,195 | -33% | -$7.34M |
|
|
ABMD
22
DELISTED
Abiomed Inc
ABMD
| $14.8M | 1.63% | 87,000 -33,000 | -28% | -$5.63M |
|
|
IMMU
23
DELISTED
Immunomedics Inc
IMMU
| $14.8M | 1.62% | 700,000 -150,000 | -18% | -$3.17M |
|
24
Eli Lilly
LLY
$657B
| $14.6M | 1.61% | 111,446 -38,554 | -26% | -$5.07M |
|
25
Merck
MRK
$210B
| $14.6M | 1.59% | 160,000 -55,000 | -26% | -$5M |
|